AMCP convened key stakeholders in managed care to address the balance between patient access and payer requirements in the FDA Accelerated Approval (AA) pathway program. Experts from various fields participated, aiming to identify gaps between FDAAA requirements and payer-valued treatment outcomes, explore evidence ecosystem opportunities, and evaluate policy options. The forum emphasized supporting drug development innovation while recognizing payer needs and promoting stakeholder trust in the AA review process. Notably, incentivizing confirmatory trials emerged as a potential impactful policy solution.
The FDA continues to approve novel therapies, but concerns arise due to the costs of certain treatments. To address this, the AMCP organized a forum to explore solutions. Stakeholders recognize the benefits of high-investment medications, but uptake of payment strategies has been slow. Gradual changes, education, and collaboration are essential to improve predictability, affordability, and accessibility for patients.
Discover how health technology assessment (HTA) and value assessment frameworks play a crucial role in evaluating pharmaceuticals and health interventions. The recent multistakeholder Partnership Forum, hosted by AMCP, delved into recognizing value within resource constraints. Key takeaways include emphasizing innovative pharmaceutical products, comprehensive data, and the need for trusted value assessments in healthcare decision-making. Explore best practices for enhancing value assessment tools and processes across the industry.
This sponsored webinar will provide disease education for population-based decision makers to inform on the concept of clinical remission and next steps in elevating clinical remission as a goal for asthma.
The Health Equity Action Brief on Geographic Inequality highlights a concerning trend of widening geographic inequality over the past four decades and what managed care can do to address these potential policy biases.
AMCP opposes attempts to erode the Employee Retirement Income Security Act (ERISA) and Medicare Part D preemption. AMCP believes that the certainty that comes with a single uniform federal standard ensures that plans subject to these laws are better able to provide access to needed medications regardless of where the patient lives or works.